medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 3

<< Back Next >>

Med Int Mex 2022; 38 (3)

Effectiveness of methylprednisolone combined with doxycycline to reduce the clinical activity of Graves orbitopathy.

Mendoza-Martínez P, Linares-Rivas CDA, Sosa-Caballero A, Domínguez-Hernández LM

Language: Spanish
References: 33
Page: 538-549
PDF size: 221.22 Kb.


ABSTRACT

Objective: To evaluate the efficacy and safety of 8 cumulative grams of methylprednisolone combined with doxycycline 50 mg/day for 12 weeks in patients with active Graves orbitopathy.
Materials and Methods: Quasiexperimental, prospective, longitudinal, before and after, open study, done from November 1st, 2016 to April 30th, 2017 at Endocrinology Department of Centro Medico Nacional La Raza, Mexico City. Patients with Graves orbitopathy with CAS (Clinical Activity Score) ≥ 3 points of the EUGOGO scale were included.
Results: There were included 15 patients, 9 women and 6 men, mean age 51.06 ± 9.75 years. The mean decrease in CAS was 2 points (95% CI, p ‹ 0.001), the mean proptosis was 1 mm (95% CI, p = 0.002), the final GO-QOL total was 40-48% (95% CI, p ‹ 0.001), 2 patients had sinusitis (95% CI, p = 0.14), 2 patients uroinfection (95% CI, p = 0.14) and 4 patients hyperglycemia (95% CI, p = 0.03); other side effects of medications there were not observed.
Conclusions: The combined scheme of methylprednisolone plus doxycycline causes a decrease in the severity and activity of Graves orbitopathy and improvement in quality of life without serious side effects.


REFERENCES

  1. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcoccie C, et al. Consensus statement of theEuropean Group on Graves’ orbitopathy (EUGOGO) onmanagement of GO. Eur J Endocrinol 2008; 158: 273-285.doi: 10.1530/EJE-07-0666.

  2. Lazarus J. Epidemiology of Graves’ orbitopathy (GO) andrelationship with thyroid disease. Clin Endocrinol Metab2012; 26: 273-279. doi: 10.1530/EJE-07-0666.

  3. Rundle FF, Wilson CV. Development and course of exophthalmosand ophthalmoplejia in Graves’ disease withspecial reference to the effect of thyroidectomy. Clin Sci1945; 5 (3-4): 177-194.

  4. Hales B, Rundle FF. Ocular changes in Graves’ disease. Q JMed 1960; 29: 113-126.

  5. Beleslin BN, Ciric J, Zarkovic M, Stojkovic M, Savic S, KnezevicM, et al. Efficacy and safety of combined parenteraland oral steroid therapy in Graves’ orbitopathy. Hormones2014; 13 (2): 222-228. doi: 10.1007/BF03401336.

  6. Bahn RS. Graves’ Ophthalmopathy. N Engl J Med 2010; 362(8): 726-738. doi: 10.1056/NEJMra0905750.

  7. Stan M, Bahn R. Risk factors for development or deteriorationof Graves’ ophthalmopathy. Thyroid 2012; 20 (7):776-783. doi: 10.1089/thy.2010.1634.

  8. Tollstedt L, Lundell G, Blomgren H, Bring J. Does early administrationof thyroxine reduce the development of Graves’ophthalmopathy after radioiodine treatment? Eur J Endocrinol1994; 130: 494-497. doi: 10.1530/eje.0.1300494.

  9. Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathyafter radioiodine therapy for Graves’ disease:prognostic factors and the role of methimazole. J ClinEndocrinol Metab 1994; 79 (2): 542-546. doi: 10.1210/jcem.79.2.7913934.

  10. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, MannK, et al. Clinical results of anti-inflammatory therapy inGraves’ ophthalmopathy and association with thyroidalautoantibodies. Clin Endocrinol (Oxf) 2004; 61: 612-618.doi: 10.1111/j.1365-2265.2004.02143.x.

  11. Salvi M, Campi I. Medical therapy of Graves’ orbitopathy.Horm Metab Res 2015; 47: 779-788. doi: 10.1055/s-0035-1554721.

  12. Bahn RS, Burch HB, Cooper DS, Garber JR, GreenleeMC, Klein I, et al. Hyperthyroidismand other causes ofthyrotoxicosis: management guidelines of the AmericanThyroid Association and American Association of ClinicalEndocrinologists. Thoroid 2011; 21 (6): 593-646. doi:10.1089/thy.2010.0417.

  13. Lai A, Sassi L, Compri E, Marino F, Silvelli P, Pientanida E, etal. Lower dose prednisone prevents radioiodine associatedexacerbation of initially mild or absent graves’ orbitopathy:a retrospective cohort study. J Clin Endocrinol Metab. 2010;95 (3): 1333-1337. doi: 10.1210/jc.2009-2130

  14. Bartalena L, Krassas G, Wiersinga W, Marcocci C, Salvi M,Daumerie C, et al. Efficacy and safety of three differentcumulative doses of intravenous methylprednisolone formoderate to severe and active Graves’ orbitopathy, J ClinEndocrinol Metab 2012; 97 (12): 4454-4463. doi: 10.1210/jc.2012-2389

  15. Dolman PJ. Evaluating Graves’ orbitopathy. Best Pract ResClin Endocrinol Metab 2012; 26: 229-248. doi: 10.1016/j.beem.2011.11.007.

  16. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, singleblind trial of intravenous versus oral steroid monotherapyin Graves’ orbitopathy. J Clin Endocrinol Metab 2005; 90(9): 5234-5240. doi: 10.1210/jc.2005-0148.

  17. Hidalgo S. Patogenia y tratamiento médico de la orbitopatíade Graves. Rev Med Clin Condes 2010; 21 (6): 930-934.

  18. Belzunce M, Garcia G. Thyroid ophthalmopathy: clinicalactivity determination of thyroid ophthalmopathy as aprognostic factor of inmunosupressive treatment response.Arch Soc Esp Oftalmol 2005; 80 (12): 705-12. doi: 10.4321/s0365-66912005001200005.

  19. Alhambra M, Gálvez M, Moreno P, Prior I, Muñoz C, López B,et al. Clinical efficacy of intravenous glucocorticoid treatmentin Graves' ophthalmopathy. Endocrinología y Nutrición 2013;60 (1): 10-14. DOI: 10.1016/j.endoen.2013.01.007.

  20. Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, MartinezH, et al. Treatment of thyroid associated ophthalmopathywith periocular injections of triamcinolone. BrJ Ophthalmol 2004; 88 (11): 1380-1386. doi: 10.1136/bjo.2004.046193.

  21. Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoidsfor Graves’ orbitopathy: efficacy and morbidity. J ClinEndocrinol Metab 2011; 96 (2): 320-332. doi: 10.1210/jc.2010-1962.

  22. Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, FenziG. High-dose intravenous corticosteroid therapy for Graves’ophthalmopathy. J Endocrinol Invest 2001; 24 (3): 152-158.doi: 10.1007/BF03343835.

  23. Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP,Wiersinga WM. Determinants of liver damage associatedwith intravenous methylprednisolone pulse therapy inGraves’ ophthalmopathy. Thyroid 2007; 17 (4): 357-362.doi: 10.1089/thy.2006.0267.

  24. Bahn R. High-dose intravenous glucocorticoid therapy forGraves’ ophthalmopathy: where are we now? Thyroid2012; 22: 1-2. doi: 10.1089/thy.2012.2201.ed.

  25. Stan MN, Garrity JA and Bahn RS. The evaluation andtreatment of Graves’ ophthalmopathy. Med Clin North Am2012; 96 (2): 311-328. doi: 10.1016/j.clim.2008.09.007.

  26. Luna MG, Gómez LG. Respuesta clínica con 8 gramos demetilprednisolona acumulados en 14 semanas en pacientescon orbitopatía de grave (tesis de especialidad). México:Hospital de especialidades Dr. Antonio Fraga Mouret.Centro Médico Nacional La Raza; 2015.

  27. Van Geest RJ, Sasim IV, Koppeschaar HP, Kalmann R,Stravers SN, Bijilsma WR et al. Methylprednisolone pulsetherapy for patients with moderately to severe Graves’orbitopathy: a prospective randomized, placebo-controlledstudy. Eur J Endocrinol 2008; 158: 229-237. doi: 10.1530/EJE-07-0558.

  28. Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P,Baister E, et al. Double-blind, placebo-controlled trial of octreotidelong-acting repeatable (LAR) in thyroid-associatedophthalmopathy. J Clin Endocrinol Metab 2004; 89 (12):5910-5915. doi: 10.1210/jc.2004-0697.

  29. Stan MN, Garrity JA, Bradley EA, Woog JJ, Bahn MM, BrennanMD, et al. Randomized, double-blind, placebo controlledtrial of long-acting release octreotide for treatment ofGraves’ ophthalmopathy. J Clin Endocrinol Metab 2006; 91(12): 4817-4824. doi: 10.1210/jc.2006-1105.

  30. Fassi D, Banga JP, Gilbert JA. Treatment of Graves’ diseasewith rituximab specifically reduces the production ofthyroid stimulating autoantibodies. Clin Exp Immunol.2009;130:252-258.

  31. Bradley EA, Gower EW, Bradley DJ, Meyer DR, Kahill KV, CusterPL, et al. Orbital radiation for Graves’ ophthalmopathy:a report by the American Academy of Ophthalmology.Ophthalmology 2008; 115 (2): 398-409. doi: 10.1016/j.ophtha.2007.10.028.

  32. Zhu W, Ye L, Shen L, Jiao Q, Huang F, Han R, et al. A prospective,randomized trial of intravenous glucocorticoidstherapy with different protocols for patients with Graves’ophthalmopathy. J Clin Endocrinol Metab 2014; 99 (6):1999-2007. doi: 10.1210/jc.2013-3919.

  33. Lin M, Mao Y, Ai S, Liu g, Zhang J, Yan J, et al. Efficacy ofsubantimicrobial dose doxycycline for moderate to severeand active Graves’ orbitopathy. Int J Endocrinol 2015; 2015:1-8. doi: 10.1155/2015/285698.




2020     |     www.medigraphic.com